Summary: Transmembrane serine/threonine kinase forming with the TGF-beta type II serine/threonine kinase receptor, TGFBR2, the non-promiscuous receptor for the TGF-beta cytokines TGFB1, TGFB2 and TGFB3. Transduces the TGFB1, TGFB2 and TGFB3 signal from the cell surface to the cytoplasm and is thus regulating a plethora of physiological and pathological processes including cell cycle arrest in epithelial and hematopoietic cells, control of mesenchymal cell proliferation and differentiation, wound healing, extracellular matrix production, immunosuppression and carcinogenesis. The formation of the receptor complex composed of 2 TGFBR1 and 2 TGFBR2 molecules symmetrically bound to the cytokine dimer results in the phosphorylation and the activation of TGFBR1 by the constitutively active TGFBR2. Activated TGFBR1 phosphorylates SMAD2 which dissociates from the receptor and interacts with SMAD4. The SMAD2-SMAD4 complex is subsequently translocated to the nucleus where it modulates the transcription of the TGF-beta-regulated genes. This constitutes the canonical SMAD-dependent TGF-beta signaling cascade. Also involved in non-canonical, SMAD-independent TGF-beta signaling pathways. For instance, TGFBR1 induces TRAF6 autoubiquitination which in turn results in MAP3K7 ubiquitination and activation to trigger apoptosis. Also regulates epithelial to mesenchymal transition through a SMAD-independent signaling pathway through PARD6A phosphorylation and activation. [UniProtKB/Swiss-Prot Function]
These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, align it with our published shRNA design sequences. If these do not align, please utilize our custom shRNA service.
OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.
For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at email@example.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).
* Delivery time in business days.Occasional delay may occur due to complexity of the constructs.
All shRNA Citations:
Mitochondrial damage and cholesterol storage in human hepatocellular carcinoma cells with silencing of UBIAD1 gene expression, Morales, CR;Grigoryeva, LS;Pan, X;Bruno, L;,
Molecular Genetics and Metabolism Reports Sep 2014
[UBIAD1] Transmembrane Domain Targeting Peptide Antagonizing ErbB2/Neu Inhibits Breast Tumor Growth and Metastasis, Arpel, A;Sawma, P;Spenlé, C;Fritz, J;Meyer, L;Garnier, N;Velázquez-Quesada, I;Hussenet, T;Aci-Sèche, S;Baumlin, N;Genest, M;Brasse, D;Hubert, P;Crémel, G;Orend, G;Laquerrière, P;Bagnard, D;,
Cell Rep Sep 2014
[ERBB2] PGC-1a mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis, LeBleu, VS;O'Connell, JT;Gonzalez Herrera, KN;Wikman, H;Pantel, K;Haigis, MC;de Carvalho, FM;Damascena, A;Domingos Chinen, LT;Rocha, RM;Asara, JM;Kalluri, R;,
Nat. Cell Biol. Sep 2014
[PPARGC1A] Leukocyte specific protein-1: A novel regulator of hepatocellular proliferation and migration deleted in human HCC, Koral, K;Paranjpe, S;Bowen, WC;Mars, W;Luo, J;Michalopoulos, GK;,
Hepatology Sep 2014
[ LSP1] Inhibition of tumor-associated avß3 integrin regulates the angiogenic switch by enhancing expression of IGFBP-4 leading to reduced melanoma growth and angiogenesis in vivo, Contois, LW;Akalu, A;Caron, JM;Tweedie, E;Cretu, A;Henderson, T;Liaw, L;Friesel, R;Vary, C;Brooks, PC;,
Angiogenesis Sep 2014
[ITG?3] Pannexin 1 and Pannexin 3 Channels Regulate Skeletal Muscle Myoblast Proliferation and Differentiation, Langlois, S;Xiang, X;Young, K;Cowan, BJ;Penuela, S;Cowan, KN;,
J. Biol. Chem. Sep 2014
[Panx3] TGF-ß1 mediates the radiation response of prostate cancer, Wu, CT;Hsieh, CC;Yen, TC;Chen, WC;Chen, MF;,
J. Mol. Med. Sep 2014
[TGFB1] Beclin-1-p53 interaction is crucial for cell fate determination in embryonal carcinoma cells, Tripathi, R;Ash, D;Shaha, C;,
J. Cell. Mol. Med. Sep 2014
[ATG5] Beclin-1-p53 interaction is crucial for cell fate determination in embryonal carcinoma cells, Tripathi, R;Ash, D;Shaha, C;,
J. Cell. Mol. Med. Sep 2014
[BECN1] Bile Acids Regulate Nuclear Receptor (Nur77) Expression and Intracellular Location to Control Proliferation and Apoptosis, Hu, Y;Chau, T;Liu, HX;Liao, D;Keane, R;Nie, Y;Yang, H;Wan, YJ;,
Mol. Cancer Res. Sep 2014
* Delivery time is an estimate in business days. Occasional delays may occur due to unforeseen complexities in the preparation of your construct. International customers may expect an additional 1-2 weeks in shipping